Intercept Pharmaceuticals Inc  

(Public, NASDAQ:ICPT)   Watch this stock  
Find more results for ICPT
240.10
+2.59 (1.09%)
Apr 17 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 227.50 - 251.00
52 week 30.38 - 497.00
Open 235.70
Vol / Avg. 523,009.00/718,960.00
Mkt cap 4.83B
P/E     -
Div/yield     -
EPS -3.70
Shares 20.12M
Beta     -
Inst. own 63%
Jun 16, 2014
Q1 2014 Intercept Pharmaceuticals Inc Earnings Release (Estimated) Add to calendar
Apr 8, 2014
Intercept Pharmaceuticals Inc at Needham Life Sciences Conference
Mar 17, 2014
Q4 2013 Intercept Pharmaceuticals Inc Earnings Conference Call
Mar 14, 2014
Q4 2013 Intercept Pharmaceuticals Inc Earnings Release
Mar 3, 2014
Intercept Pharmaceuticals Inc at Cowen Health Care Conference
Feb 26, 2014
Intercept Pharmaceuticals Inc at RBC Capital Markets Healthcare Conference
Feb 26, 2014
Intercept Pharmaceuticals Inc at Citi Global Healthcare Conference
Feb 13, 2014
Intercept Pharmaceuticals Inc at Leerink Swann Global Healthcare Conference
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '13) 2013
Net profit margin -3050.80% -4180.51%
Operating margin -3430.44% -2432.84%
EBITD margin - -2426.33%
Return on average assets -32.09% -51.65%
Return on average equity -57.23% -91.41%
Employees 50 -
CDP Score - -

Address

SUITE 505, 450 W. 15TH STREET
NEW YORK, NY 10011
United States - Map
+1-646-7471000 (Phone)
+1-646-7471001 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Intercept Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of therapeutics to treat chronic liver diseases utilizing its bile acid chemistry.The Company�s product candidate, obeticholic acid, or OCA, is a bile acid analog, a chemical substance that has a structure based on a naturally occurring human bile acid. It is developing OCA initially for primary biliary cirrhosis, or PBC, as a second line treatment for patients who have an inadequate response to or who are unable to tolerate standard of care therapy and therefore need additional treatment. The Company is conducting a Phase 3 clinical trial of OCA in PBC, which it calls the POISE trial, that serves as the basis for seeking regulatory approval in the United States and Europe. As of December 19, 2012, the Company completed enrollment of the POISE trial with 217 patients.

Officers and directors

Lorenzo Tallarigo M.D. Independent Chairman of the Board
Age: 63
Bio & Compensation  - Reuters
Mark Pruzanski M.D. President, Chief Executive Officer, Director
Age: 45
Bio & Compensation  - Reuters
Barbara G. Duncan Chief Financial Officer, Treasurer, Secretary
Age: 49
Bio & Compensation  - Reuters
David Shapiro M.D. Chief Medical Officer, Executive Vice President - Development
Age: 58
Bio & Compensation  - Reuters
Luciano Adorini M.D. Chief Scientific Officer
Age: 65
Bio & Compensation  - Reuters
Daniel P. Regan Chief Commercial Officer
Age: 49
Bio & Compensation  - Reuters
Srinivas Akkaraju M.D., Ph.D. Director
Age: 45
Bio & Compensation  - Reuters
Sanj K. Patel Director
Age: 44
Bio & Compensation  - Reuters
Glenn P. Sblendorio Director
Age: 58
Bio & Compensation  - Reuters
Paolo Fundaro Independent Director
Age: 39
Bio & Compensation  - Reuters